News >

Targeted Agents Show Promise in Cholangiocarcinoma

Jason Harris
Published: Tuesday, Mar 31, 2020

Aiwu Ruth He, MD, PhD

Aiwu Ruth He, MD, PhD

Cholangiocarcinoma (CCA) is both rare and aggressive, and the current systemic standard of care, gemcitabine plus cisplatin, produces only modest results. However, targeted agents such as the FGFR inhibitors pemigatinib and infigratinib (BGJ398), and the IDH1 inhibitor ivosidenib (Tibsovo) have shown encouraging activity in clinical trials and may represent the future of care in this disease with a high unmet need, said Aiwu Ruth He, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication